Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis

Viruses prompt oncogenic transformation by genetically altering infected cells. Several recent studies have demonstrated that viruses alter the expression of microRNAs, non-coding RNA molecules that can block the expression of target genes.

17 Jan 2013

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

Breast cancer is the second leading cause of cancer deaths among women in the United States. Many of these deaths occur when there is an initial diagnosis of invasive or metastatic disease. A protein called NEDD9-which regulates cell migration, division and survival-has been linked to tumor invasion and metastasis in a variety of cancers.

16 Jan 2013

Aggressive breast cancer’s metastasis molecular switch identified

Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.

15 Jan 2013

Beta blocker use linked to NSCLC patient survival

Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.

14 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

Scientists discover process by which mda-9/syntenin contributes to melanoma metastasis

After recently announcing success in eliminating melanoma metastasis in laboratory experiments, scientists at Virginia Commonwealth University Massey Cancer Center have made another important discovery in understanding the process by which the gene mda-9/syntenin contributes to metastasis in melanoma (the spread of skin cancer) and possibly a variety of other cancers.

4 Jan 2013

Cancer-associated inflammation boosts ADAR1 enzyme activity

An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence.

25 Dec 2012

Optic nerve assessment predicts retinoblastoma outcomes

Magnetic resonance imaging scans taken pre- and post-neoadjuvant chemotherapy for International Retinoblastoma Staging System stage III retinoblastoma can indicate a patient's likely event-free and overall survival, indicate study results.

22 Dec 2012

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.

21 Dec 2012

Researchers develop game-changing diagnostic and prognostic genetic tests for prostate cancer

Researchers at the Kimmel Cancer Center at Jefferson (KCC) have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant cancers.

21 Dec 2012

Investigators report non-coding miRNAs as appealing biomarkers for cancer malignancy

As many as 50 percent of all human protein-coding genes are regulated by microRNA (miRNA) molecules. While some miRNAs impact onset and progression of cancer, others can actually suppress the development of malignant tumors and are useful in cancer therapy. They can also serve as potential biomarkers for early cancer detection. In a new issue of Cancer Biomarkers, investigators report on non-coding miRNAs as appealing biomarkers for malignancy.

20 Dec 2012

MiR-181 molecule tied to breast cancer metastasis

Researchers at Case Western Reserve University School of Medicine have identified a molecule linked to more aggressive forms of breast cancer - a discovery that could point the way to potential cures.

18 Dec 2012

PRSS3 enzyme linked to aggressive prostate cancer

Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer.

18 Dec 2012

New MIT technology may help make cancer biomarker detection much easier

Finding ways to diagnose cancer earlier could greatly improve the chances of survival for many patients. One way to do this is to look for specific proteins secreted by cancer cells, which circulate in the bloodstream. However, the quantity of these biomarkers is so low that detecting them has proven difficult.

17 Dec 2012

American Thoracic Society, IASLC and ERS propose new sub-classification of lung adenocarcinomas

The International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS), have proposed a new sub-classification of lung adenocarcinomas.

16 Dec 2012

Study describes new, paradoxical characteristics of HER2-negative breast cancer

A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis and treatment of breast cancer.

15 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.